PMID- 15063833
OWN - NLM
STAT- MEDLINE
DCOM- 20040809
LR  - 20121115
IS  - 1537-1891 (Print)
IS  - 1537-1891 (Linking)
VI  - 40
IP  - 6
DP  - 2004 Jan
TI  - Continuous administration of heparin in patients with deep vein thrombosis can 
      increase plasma levels of diamine oxidase.
PG  - 293-300
AB  - Besides its anticoagulant activity, the sulfated polysaccharide heparin has 
      numerous other biological effects. Especially the antiinflammatory and 
      immunoregulatory properties of heparin may be associated with its ability to 
      release the histamine-degrading enzyme diamine oxidase (DAO) from tissue-bound 
      sites into the circulation. Whereas DAO activity is at the limits of detection in 
      normal human plasma, the application of heparin leads to a significant increase 
      of plasma DAO activity. However, previously, only the effect of bolus injection 
      of unfractionated heparin (UFH) had been studied. To investigate DAO release 
      during continuous heparin infusion, 28 patients with deep vein thrombosis (DVT) 
      undergoing heparin therapy were analyzed. Whereas continuous heparin infusion did 
      not lead to any increase of plasma DAO activity in 12 patients (43%), 6 patients 
      (21%) showed a single elevated and 10 patients (36%) permanently elevated plasma 
      DAO activity. The groups of patients exhibiting different DAO release responses 
      did not differ in age, sex, body weight, concomitant diseases, heparin infusion 
      rates, coagulation indices, location and extension of thrombosis, or clinical 
      outcome. However, the rate of idiopathic DVT was significantly higher in the 
      group of patients releasing DAO. This study shows, for the first time, that 
      continuous heparin infusion can lead to DAO release and that individuals exhibit 
      considerable differences in their release response. Although the significance of 
      heparin-induced DAO release needs further clarification, our results indicate 
      that postheparin plasma DAO activity could be an interesting parameter correlated 
      with idiopathic DVT.
FAU - Klocker, Josef
AU  - Klocker J
AD  - Klinische Abteilung fur Gefasschirurgie, Universitatsklinik fur Chirurgie, 
      Universitat Innsbruck, Austria.
FAU - Perkmann, Reinhold
AU  - Perkmann R
FAU - Klein-Weigel, Peter
AU  - Klein-Weigel P
FAU - Morsdorf, Gabriele
AU  - Morsdorf G
FAU - Drasche, Astrid
AU  - Drasche A
FAU - Klingler, Anton
AU  - Klingler A
FAU - Fraedrich, Gustav
AU  - Fraedrich G
FAU - Schwelberger, Hubert G
AU  - Schwelberger HG
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Vascul Pharmacol
JT  - Vascular pharmacology
JID - 101130615
RN  - 0 (Anticoagulants)
RN  - 9005-49-6 (Heparin)
RN  - EC 1.4.3.21 (Amine Oxidase (Copper-Containing))
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Amine Oxidase (Copper-Containing)/*blood
MH  - Anticoagulants/*administration & dosage/therapeutic use
MH  - Drug Administration Schedule
MH  - Female
MH  - Heparin/*administration & dosage/therapeutic use
MH  - Humans
MH  - Infusions, Intravenous
MH  - Male
MH  - Middle Aged
MH  - Partial Thromboplastin Time
MH  - Treatment Outcome
MH  - Venous Thrombosis/*drug therapy/enzymology
EDAT- 2004/04/06 05:00
MHDA- 2004/08/10 05:00
CRDT- 2004/04/06 05:00
PHST- 2003/10/13 00:00 [received]
PHST- 2003/10/13 00:00 [revised]
PHST- 2004/02/23 00:00 [accepted]
PHST- 2004/04/06 05:00 [pubmed]
PHST- 2004/08/10 05:00 [medline]
PHST- 2004/04/06 05:00 [entrez]
AID - S1537189104000230 [pii]
AID - 10.1016/j.vph.2004.02.002 [doi]
PST - ppublish
SO  - Vascul Pharmacol. 2004 Jan;40(6):293-300. doi: 10.1016/j.vph.2004.02.002.